Cervix Cancer Clinical Trial
— FEMINICOLOfficial title:
Impact of a Sexological Follow-up on the Sexual Function in Patients With Cervix or Vaginal Cancer Treated by Radiotherapy and Brachytherapy
Verified date | March 2022 |
Source | Institut Claudius Regaud |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Prospective, monocentric study evaluating the impact of a nurse-led sexological follow-up on sexual function in patients with cervix or vaginal cancer treated by radiotherapy and brachytherapy. The study procedure will consist of nurse-led sexological consultations, beginning before brachytherapy and until 2 months after brachytherapy. Evolution of female sexual function and vaginal symptoms will be done through clinical examinations and completion of quality of life and female sexual function questionnaires during radiation oncologist consultation and/or nurse-led sexological consultations until one year after end of brachytherapy. Study participation of each patient will be 12 months.
Status | Completed |
Enrollment | 60 |
Est. completion date | February 20, 2022 |
Est. primary completion date | February 20, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. 18 years or older 2. Woman diagnosed with cervix or vaginal cancer, for whom a treatment by radiotherapy and brachytherapy has been decided 3. Patient receiving for the first time an utero-vaginal or vaginal brachytherapy at "Institut Universitaire du Cancer de Toulouse - Oncopole" 4. Easter Cooperative Oncology Group (ECOG) Performance Status = 2 5. All patients are eligible, regardless of their relationship status (in couple or not), their sexual orientation, and their hormonal status 6. Patient willing to give informed consent before the study and before performing any study-related procedures 7. Patient affiliated to a Social Health Insurance in France Exclusion Criteria: 1. Patient not understanding the French language 2. Patient for whom surgical treatment and brachytherapy has been decided 3. Any psychological, familial, sociological or geographical condition that potentially hampers compliance with the study protocol and follow-up after treatment discontinuation schedule 4. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice |
Country | Name | City | State |
---|---|---|---|
France | Institut Universitaire du Cancer de Toulouse - Oncopole | Toulouse |
Lead Sponsor | Collaborator |
---|---|
Institut Claudius Regaud |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Female Sexual Function Index score (evolution between inclusion and 1 year after brachytherapy) assessed using FSFI (Female Sexual Function Index) Questionnaire | 12 months for each patient | ||
Secondary | Quality of life assessed using QLQ-C30 questionnaire (Quality of Life Questionnaire-Core 30) | 12 months for each patient | ||
Secondary | Quality of life specific for cervix cancer assessed using QLQ-CX24 questionnaire (Quality-of-Life questionnaire cervical cancer module) | 12 months for each patient | ||
Secondary | Vaginal symptoms assessed using NCI-CTCAE version 5 (National Cancer Institute Common Toxicity Criteria for Adverse Events) | 12 months for each patient |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04067882 -
Validation of the Genetic Signature 354849 as a Prognostic Method
|
||
Completed |
NCT00329589 -
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
|
Phase 1 | |
Recruiting |
NCT05743517 -
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
|
N/A | |
Completed |
NCT05234112 -
Prevention and Screening Towards Elimination of Cervical Cancer
|
N/A | |
Completed |
NCT04258553 -
Thiol Disulfide Balance in Cervix Cancer
|
||
Active, not recruiting |
NCT04357873 -
Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
|
Phase 2 | |
Completed |
NCT00509444 -
Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial
|
Phase 3 | |
Completed |
NCT00379743 -
Partnership for Healthy Seniors
|
N/A | |
Recruiting |
NCT06022029 -
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
|
Phase 1 | |
Recruiting |
NCT06116019 -
Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
|
||
Completed |
NCT04072913 -
Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix
|
N/A | |
Active, not recruiting |
NCT06452004 -
Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC)
|
N/A | |
Recruiting |
NCT04651127 -
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010875 -
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT02552121 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02001623 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02997553 -
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
|
Phase 3 | |
Terminated |
NCT02233387 -
PET CT With HX4 in Cervix Cancer
|
Phase 2 | |
Completed |
NCT01766284 -
Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix
|
N/A | |
Completed |
NCT00122772 -
CRP on Radiobiological and Clinical Studies on Viral-Induced Cancer's Response to Radiotherapy
|
Phase 3 |